India's Hetero wins approval to launch COVID-19 drug favipiravir

India's Hetero Labs Ltd said on Wednesday it received local regulatory approval to launch its version of anti-viral drug favipiravir for the treatment of COVID-19.

BENGALURU, July 29 (Reuters) - India's Hetero Labs Ltd said on Wednesday it received local regulatory approval to launch its version of anti-viral drug favipiravir for the treatment of COVID-19.

The drug, priced at 59 rupees (79 cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said.

($1 = 74.7800 Indian rupees)

(Reporting by Sachin Ravikumar; Editing by Saumyadeb Chakrabarty)

((saisachin.r@tr.com; +91 80 6182 2754; Twitter: @sachinr27;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More